Long-term remission with eculizumab in atypical haemolytic uraemic syndrome

被引：2
|
作者：
Carter, Simon [1 ]
Hewitt, Ian [4 ]
Kausman, Joshua [1 ,2 ,3 ]
机构：
[1] Royal Childrens Hosp, Melbourne, Vic, Australia
[2] Murdoch Childrens Res Inst, Murdoch, WA, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Princess Margaret Hosp, Perth, WA, Australia
来源：
NEPHROLOGY | 2017年 / 22卷
关键词：
atypical haemolytic uraemic syndrome; eculizumab; long term outcome; paediatric; safety profile;
D O I：
10.1111/nep.12932
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The understanding of the role of complement dysregulation in atypical haemolytic uraemic syndrome (aHUS) has led to major changes in therapeutic approaches and outcomes. Eculizumab is a humanized anti-C5 monoclonal antibody that inhibits the terminal complement pathway and has revolutionized the treatment and prognosis of aHUS. However, published reports to date have had relatively short-term follow-up. We report two paediatric cases of aHUS successfully treated with eculizumab longer than 6years with no serious adverse events and preservation of renal function.
引用
收藏
页码：7 / 10
页数：4
相关论文
共 50 条
  • [21] Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement
    Hushi Hu
    Arvind Nagra
    Mushfequr R. Haq
    Rodney D. Gilbert
    Pediatric Nephrology, 2014, 29 : 1103 - 1106
  • [22] Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement
    Hu, Hushi
    Nagra, Arvind
    Haq, Mushfequr R.
    Gilbert, Rodney D.
    PEDIATRIC NEPHROLOGY, 2014, 29 (06) : 1103 - 1106
  • [23] ECULIZUMAB IN ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) PATIENTS WITH OR WITHOUT PRIOR TRANSPLANT
    Legendre, Christophe
    Cohen, David
    Feldkamp, Thorsten
    Fouque, Denis
    Furman, Richard
    Gaber, A. Osama
    Greenbaum, Larry
    Goodship, Timothy
    Haller, Hermann
    Herthelius, Maria
    Hourmant, Maryvonne
    Licht, Christoph
    Sheerin, Neil
    Trivelli, Antonelli
    Bedrosian, Camille
    Loirat, Chantal
    TRANSPLANT INTERNATIONAL, 2013, 26 : 176 - 176
  • [24] Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
    Zuber, Julien
    Fakhouri, Fadi
    Roumenina, Lubka T.
    Loirat, Chantal
    Fremeaux-Bacchi, Veronique
    NATURE REVIEWS NEPHROLOGY, 2012, 8 (11) : 643 - 657
  • [25] Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
    Duran, Carlos E.
    Blasco, Miquel
    Maduell, Francisco
    Campistol, Josep M.
    CLINICAL KIDNEY JOURNAL, 2012, 5 (01): : 28 - 30
  • [26] Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab?
    Smith-Jackson, Kate
    Marchbank, Kevin J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [27] Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
    Julien Zuber
    Fadi Fakhouri
    Lubka T. Roumenina
    Chantal Loirat
    Véronique Frémeaux-Bacchi
    Nature Reviews Nephrology, 2012, 8 : 643 - 657
  • [28] Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions
    Bekassy, Zivile D.
    Kristoffersson, Ann-Charlotte
    Cronqvist, Mats
    Roumenina, Lubka T.
    Rybkine, Tania
    Vergoz, Laura
    Hue, Christophe
    Fremeaux-Bacchi, Veronique
    Karpman, Diana
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (11) : 2899 - 2907
  • [29] Atypical haemolytic uraemic syndrome
    Kavanagh, David
    Goodship, Timothy H. J.
    Richards, Anna
    BRITISH MEDICAL BULLETIN, 2006, 77-78 : 5 - 22
  • [30] Outcomes from an observational clinical trial evaluating the long-term safety and effectiveness of eculizumab use in paediatric patients with atypical haemolytic uraemic syndrome (aHUS)
    Pape, L.
    Mix, C.
    Wang, J.
    Greenbaum, L.
    Lapeyraque, A-L.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1757 - 1757
12345